UC Davis Comprehensive Cancer Center names physician-in-chief

Richard Bold, MD
Richard Bold, MD

Richard Bold, MD, has been named physician-in-chief of UC Davis Comprehensive Cancer Center.

Bold will have clinical oversight of outpatient and inpatient services, as well as the center center’s affiliated UC Davis Health Cancer Care Network sites.

Bold’s appointment is part of a broader effort to integrate the cancer center’s research clinical trials, training, education and community outreach into clinical oncology services.

In his new role, Bold will be responsible for advancing patient-centered care as well as setting the quality agenda and managing relationships among the various cancer center clinical activities, including UC Davis Health and UC Davis Cancer Care Network sites.

He also will lead the development and oversight of the cancer center’s performance targets, benchmarks and metrics, aiming to enhance patient access to high-quality cancer care, ensure integration of cancer clinical trials into clinical operations, establishing best practices, and measuring and improving patient outcomes.

Richard Bold, MD
Richard Bold, MD

Richard Bold, MD, has been named physician-in-chief of UC Davis Comprehensive Cancer Center.

Bold will have clinical oversight of outpatient and inpatient services, as well as the center center’s affiliated UC Davis Health Cancer Care Network sites.

Bold’s appointment is part of a broader effort to integrate the cancer center’s research clinical trials, training, education and community outreach into clinical oncology services.

In his new role, Bold will be responsible for advancing patient-centered care as well as setting the quality agenda and managing relationships among the various cancer center clinical activities, including UC Davis Health and UC Davis Cancer Care Network sites.

He also will lead the development and oversight of the cancer center’s performance targets, benchmarks and metrics, aiming to enhance patient access to high-quality cancer care, ensure integration of cancer clinical trials into clinical operations, establishing best practices, and measuring and improving patient outcomes.